Beam Therapeutics (BEAM) Operating Leases (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Operating Leases data on file, last reported at $135.8 million in Q1 2026.

• On a quarterly basis, Operating Leases fell 6.26% year-over-year to $135.8 million in Q1 2026; TTM through Mar 2026 was $135.8 million, a 6.26% decrease from a year earlier, with the FY2025 full-year figure at $139.8 million, down 5.54% from the prior year.
• Operating Leases for Q1 2026 stood at $135.8 million, down from $139.8 million in the prior quarter.
• Over the last five years, Operating Leases for BEAM reached as high as $168.6 million in Q4 2022 and fell as low as $135.8 million in Q1 2026.
• Historically, Operating Leases has averaged $152.4 million across 5 years, with a median of $152.6 million in 2024.
• Across the five-year window, Operating Leases gained 25.08% in 2022 and slipped 7.48% in 2024, its largest moves.
• Year by year, Operating Leases stood at $168.6 million in 2022, then decreased by 5.17% to $159.9 million in 2023, then slipped by 7.48% to $148.0 million in 2024, then declined by 5.54% to $139.8 million in 2025, then decreased by 2.8% to $135.8 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $135.8 million in Q1 2026, $139.8 million in Q4 2025, and $138.7 million in Q3 2025.